Which drug is an anabolic agent used in osteoporosis management?

Prepare for the Menopause Society Exam with tailored quizzes and detailed explanations. Your journey to certification starts here!

Multiple Choice

Which drug is an anabolic agent used in osteoporosis management?

Explanation:
Anabolic therapy for osteoporosis aims to build new bone by stimulating osteoblast activity. Teriparatide is a recombinant parathyroid hormone fragment given as daily injections; when exposure is intermittent, it preferentially promotes bone formation rather than bone resorption. This leads to increases in bone mineral density and a reduction in fracture risk, especially in individuals at high fracture risk or those who have not benefited from antiresorptives or have glucocorticoid-induced osteoporosis. In contrast, the other agents are antiresorptives: alendronate inhibits osteoclast-mediated bone breakdown, denosumab blocks RANKL to reduce resorption, and raloxifene—a selective estrogen receptor modulator—also acts mainly to decrease bone resorption and does not provide the same anabolic bone-building effect.

Anabolic therapy for osteoporosis aims to build new bone by stimulating osteoblast activity. Teriparatide is a recombinant parathyroid hormone fragment given as daily injections; when exposure is intermittent, it preferentially promotes bone formation rather than bone resorption. This leads to increases in bone mineral density and a reduction in fracture risk, especially in individuals at high fracture risk or those who have not benefited from antiresorptives or have glucocorticoid-induced osteoporosis.

In contrast, the other agents are antiresorptives: alendronate inhibits osteoclast-mediated bone breakdown, denosumab blocks RANKL to reduce resorption, and raloxifene—a selective estrogen receptor modulator—also acts mainly to decrease bone resorption and does not provide the same anabolic bone-building effect.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy